stockrow
Friday 6 November 2026
Export LNSR’s income statement to Excel — free account
LENSAR, Inc.
LNSR Healthcare Medical Devices
LENSAR, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $58.4 million, up 9.24% from fiscal 2024.
- Revenue
- +18.4%
- EPS
- +291.7%
- Free cash flow
- +96.8%
Quarter to June 2026, against a year earlier
5.39
0.11
−2.00%
Follow LNSR
Alert me
LENSAR, Inc. (LNSR) P/E ratio
As of 5 November 2026, LENSAR, Inc. (LNSR) trades at a P/E ratio of 3.9×. Over the past ten years it has ranged from 0.0× (March 2026) to 6.5× (August 2026); the current reading is higher than 90% of that period. That is below the Medical Devices industry median of 25.6× and below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 4.0× | (33.76%) |
| Mar 2026 | 6.1× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 24 more quarters | Free account |
Against its own ten years
Low 0.0×
High 6.5×
Ten-year median
0.0×
Current reading's percentile
90
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LUCD Lucid Diagnostics Inc. compare | n/m |
| ECOR electroCore, Inc. compare | n/m |
| MBOT Microbot Medical Inc. compare | n/m |
| SERA Sera Prognostics, Inc. compare | n/m |
| COCH Envoy Medical, Inc. compare | n/m |
| NYXH Nyxoah SA compare | n/m |
| OM Outset Medical, Inc. compare | n/m |
| HYPR Hyperfine, Inc. compare | n/m |
| LNSR LENSAR, Inc. | 3.9× |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)